Actively Recruiting
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Led by RasCal Therapeutics, Inc. · Updated on 2026-03-18
134
Participants Needed
3
Research Sites
308 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.
CONDITIONS
Official Title
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Pathologically confirmed advanced or metastatic malignancy
- Intolerant to or refractory to existing therapies known to benefit their condition
- Disease has progressed after standard therapy
- Evaluable or measurable tumor(s) by standard assessments applicable to their cancer
- Adequate performance status as measured by ECOG
- Tumors with documented RAS mutations or glioblastoma with or without RAS mutation
You will not qualify if you...
- Receiving cancer therapy at enrollment
- Clinically significant disease affecting a major organ system
- Significant cardiovascular disease or ECG abnormalities
- Known Gilbert's disease
- Previous or current malignancy other than target cancer within 2 years
- Intermittent hypokalemia
- Grade 1 or higher nausea, vomiting, or diarrhea at baseline due to underlying disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
University of California, Los Angeles (UCLA) Department of Medicine - Hematology/Oncology
Los Angeles, California, United States, 90404
Actively Recruiting
2
Sarah Cannon, SCRI Oncology Partners - Health One
Denver, Colorado, United States, 80218
Actively Recruiting
3
Sarah Cannon, SCRI Oncology Partners
Nashville, Tennessee, United States, 37203
Actively Recruiting
Research Team
B
Bonnie Wettersten, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here